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ABSTRACT
A series of analogues of Amb639752, a novel diacylglycerol kinase (DGK) inhibitor recently discovered by
us via virtual screening, have been tested. The compounds were evaluated as DGK inhibitors on a, h, and
f isoforms, and as antagonists on serotonin receptors. From these assays emerged two novel compounds,
namely 11 and 20, which with an IC50 respectively of 1.6 and 1.8 mM are the most potent inhibitors of
DGKa discovered to date. Both compounds demonstrated the ability to restore apoptosis in a cellular
model of X-linked lymphoproliferative disease as well as the capacity to reduce the migration of cancer
cells, suggesting their potential utility in preventing metastasis. Finally, relying on experimental biological
data, molecular modelling studies allow us to set a three-point pharmacophore model for DGK inhibitors.
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1. Introduction
Diacylglycerol kinases (DGKs) are a large family of enzymes that
share a common catalytic activity: the phosphorylation of diacyl-
glycerol (DAG) to phosphatidic acid (PA). Remarkably, both the
substrate (DAG) and the product (PA) of the DGK-catalysed reac-
tion, are bioactive lipids that can act as second messengers1. DGK
activity consequently serves as a switch to simultaneously dampen
DAG-mediated signals and boost PA-mediated signals2. Ten mam-
malian DGK isoforms (a, b, c, d, e, f, g, h, i, and r) have been iden-
tified and divided into five groups (type I–V) according to their
structural features3,4. The expression of these isoforms varies
depending on the cell type. Among the 10 isoforms, the a isoform
is among the most studied and characterised. This kinase is highly
expressed in the brain, spleen, and thymus and, along with h iso-
form, in the bone marrow. This enzyme is also highly expressed in
T-lymphocytes, where it acts together with DGKf as negative
regulator of the T-cell receptor (TCR) response, and a mediator of
IL-2 mediated proliferation3,5. The biological relevance of DGKa is
best demonstrated in patients with X-linked lymphoproliferative
disease (XLP-1), who experience life-threatening, uncontrolled
accumulation of CD8þ T cells in response to the Epstein–Barr virus
(EBV) infection6. In those patients, germline mutations of the
adaptor protein SAP (SH2D1A) perturb TCR signalling and render
DGKa constitutively active7. Deregulated DGKa activity renders
patient-derived lymphocytes resistant to reactivation-induced cell
death (RICD). Thus, antigen-activated lymphocytes accumulate in
lymphonodes and liver, resulting in severe immunopathology8.
Importantly, DGKa inhibitors restore RICD sensitivity in vitro and
in vivo, thus avoiding immunopathology and suggesting a puta-
tive therapeutic use of those molecules in XLP-19.
Apart from T-cell regulation, DGKa also plays a role in cancer,
mediating numerous aspects of cancer cell progression including
survival10,11, migration and invasion of cancer cells12–14. In particu-
lar, it has been reported that DGKa is over expressed in hepatocel-
lular carcinoma15, and melanoma cells11 while other reports
suggested that the growth of colon and breast cancer cell lines
was significantly inhibited by DGKa-siRNA16 and DGKa/atypical
PKC/b1 integrin signalling pathway was crucial for matrix invasion
of breast carcinoma cells17. In addition, expression is also higher
in lymphonodal metastasis than in breast and gastric original
tumour18,19. Finally, knock down of DGKa impairs glioblastoma
tumorigenesis20,21.
For all these reasons, the identification of strong and selective
DGKa inhibitors, it is an important field of research. To date, only
a handful of two-digit micromolar inhibitors of DGKa have been
identified, but only three were the most characterised, namely,
R59949, R59022, and ritanserin (Figure 1).
In our assay system, R59949 and R59022 have an IC50 of 11
and 20 mM, respectively9. Their efficacy has been evaluated in vivo
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studies on mice, and is limited by their rapid clearance
(t1/2¼2 h)22. Furthermore, these two inhibitors are also able to
target different isoforms of DGK, in particular R59022 acts on type
III and V (e e h), while R59949 on type I and II (c, d e j)23,24 and a
study conducted by Boroda et al. recently demonstrated their
strong antagonistic activity on 5-HT2 receptors (R59022 IC50
5HT2A¼2.2 nM; R5994 IC50 5HT2A¼9.2 nM)25.
A search on ChEMBL database26 (https://www.ebi.ac.uk/
chembl/) show how these two molecules have activity at the
same range of concentration with other biological targets, behav-
ing like a sort of promiscuous ligands. Ritanserin, a well-known
serotoninergic antagonist, is structurally similar to R59022, differ-
ing for an H-F isosteric substitution on a phenyl ring. Despite this
small modification, Boroda et al. showed that ritanserin was a
DGKa inhibitor (IC50¼15 mM) more potent than R59022 and
R59949 and with a better pharmacokinetic profile (t1/2¼40 h in
human)25. However, the comparison of ritanserin IC50 as serotonin
antagonist and as DGKa inhibitor, 0.9 nM and 15,000 nM, respect-
ively, reveal that ritanserin is much a powerful serotonin antagon-
ist than a DGK inhibitor. In addition, ritanserin is also a potent
inhibitor on dopaminergic receptors with an IC50 of 69 nM
27.
Due to these drawbacks, at the beginning, in order to elimin-
ate the strong serotoninergic activity of R59949, we reasoned to
replace its protonable nitrogen atom, which at physiologically pH
mimics the amino group of serotonin, with a carbon atom. We
decided therefore to synthesise compound 1 (Figure 2) (see sup-
porting information for its synthesis and a complete characterisa-
tion) and to test it as DGKa inhibitor.
Interestingly, the compound was totally devoid of inhibitory
activity on the enzyme, showing the importance of the basic
nitrogen atom not only for the anti-serotoninergic activity, but
also for the interaction with the kinase. With this in mind, we
recently used an in-silico approach based on chemical homology
with the two commercially available DGKa inhibitors R59022 and
R59949 using the programmes ROCS28 and EON29. From this
study, we identified a compound, Amb639752 (Figure 2), featuring
a lower IC50 for DGKa than ritanserin (IC50¼17 mM), a better select-
ivity for the a-isoform and devoid of anti-serotoninergic activity.
Along with CU-3, which features an IC50 of 0.6 mM on DGKa
30 but
contains a reactive Michael acceptor31, Amb639752 is the most
effective pharmacological tool available to study DGKa9. In this
manuscript, we report the structure–activity studies on
Amb639752 and, in combination with data on ritanserin, the gen-
eration of a pharmacophore model for this class of compounds,
which could be useful for the identification of other potential
DGKa inhibitors.
2. Methods
2.1. Chemistry procedures
Commercially available reagents and solvents were used without
further purification. Toluene were distilled immediately before use
from Na/benzophenone under a slight positive atmosphere of dry
nitrogen. Dichloromethane was dried by distillation from P2O5 and
stored on activated molecular sieves (4 Å). When needed the reac-
tions were performed in flame- or oven-dried glassware under a
positive pressure of dry nitrogen. Melting points were determined
in open glass capillary with a Stuart scientific SMP3 apparatus and
are uncorrected. All compounds were checked by IR (FT-IR
THERMO-NICOLET AVATAR), 1H and 13C APT (JEOL ECP 300MHz
spectrometer), and mass spectrometry (Thermo Finningan LCQ-
deca XP-plus, San Jose, CA) equipped with an ESI source and an
ion trap detector. Chemical shifts are reported in parts per million
(ppm). Flash column chromatography was performed on silica gel
(Merck Kieselgel 60, 230–400 mesh ASTM, Kenilworth, NJ). Thin
layer chromatography (TLC) was carried out on 5 20 cm plates
with a layer thickness of 0.25mm (Merck Silica gel 60 F254,
Kenilworth, NJ). When necessary they were developed with
KMnO4 reagent. Purity of tested compounds was established by
elemental analysis. Elemental analysis (C, H, N) of the target com-
pounds is within ±0.4% of the calculated values, confirming
95% purity.
2.1.1. Preparation of 2-chloro-1-(2,6-dimethyl-1H-indol-3-yl)ethan-
1-one (5)
In a Schlenk tube, under nitrogen, 2,6-dimethyl-1H-indole (3)
(0.20 g, 1.38mmol, 1 eq) was dissolved in 4mL of dichloroethane
dry and 0.25mL of DBU (1.66mmol, 1.2 eq) were added. The
resulting solution was heated at 90 C. When reached this tem-
perature, chloroacetyl chloride (4) (0.12mL, 1.52mmol, 1.1 eq) was
added. The reaction was stirred for 30min, then solvent was
evaporated and the crude purified by column chromatography
using PE/EtOAc 7:3 and PE/EtOAc 5:5 as eluants to give 270mg of
product as violet solid: yield 90%; m.p. 243.7–244.2 C; 1H NMR
(300MHz, DMSO-d6) d 11.88 (br s, NH), 7.85 (d, J¼ 7.9 Hz, 1H), 7.18
(s, 1H), 6.99 (d, J¼ 8.0 Hz, 1H), 4.89 (s, 2H), 2.68 (s, 3H), 2.39 (s,
3H). MS (ESI) m/z: 222 [MþH]þ.
2.1.2. Preparation of tert-butyl 4-(2-(2,6-dimethyl-1H-indol-3-yl)-2-
oxoethyl)piperazine-1-carboxylate (6)
Under nitrogen, 200mg of 5 (0.90mmol, 1 eq) was dissolved in
toluene dry, then N-Boc-piperazine (0.17 g, 0.90mmol, 1 eq),
K2CO3 (0.32 g, 2.25mmol, 2.5 eq), and KI (0.015 g, 0.09mmol,
Figure 1. Three of the most studied DGKa inhibitors.
Figure 2. Structures of the deaza analogue of R59949 and Amb639752.
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0.1 eq) were added. The reaction was heated at 80 C overnight.
Solvent was evaporated and the crude was purified by column
chromatography using PE/EtOAc 4:6 and PE/EtOAc 2:8 as eluants
to give 215mg of product as yellow amorphous solid: yield 63%;
1H NMR (300MHz, CDCl3) d 8.52 (br s, NH), 7.77 (d, J¼ 8.2 Hz, 1H),
7.12 (s, 1H), 7.08 (d, J¼ 8.0 Hz, 1H), 3.79 (s, 2H), 3.47–3.43 (m, 6H),
2.75 (s, 3H), 2.64 (br s, 2H), 2.44 (s, 3H), 1.47 (s, 9H). IR (KBr): 3190,
2964, 1698, 1413, 1417, 1364, 1126, 806 max/cm
1. MS (ESI) m/z:
372 [MþH]þ.
2.1.3. Preparation of 1-(2,6-dimethyl-1H-indol-3-yl)-2-(piperazin-1-
yl)ethan-1-one (7)
Two hundred and fifteen milligrams of 6 (0.58mmol, 1 eq) were
dissolved in dichloromethane dry. The resulting solution was
cooled at 0 C and 0.69mL of trifluoroacetic acid (9.28mmol,
16 eq) was added. After 3 h, the reaction was worked up adding
NaOH 2 M solution until pH ¼ 12. Then, NaCl solid was added
and the solution was extracted with THF (x2). The combined
organic phases were dried on sodium sulphate. After evaporation
of the solvent, the crude was purified by column chromatography
using EtOAc/MeOH 9:1 and MeCN/NH3 9:1 as eluants to give
103mg of the product as yellowish solid: yield: 65%; m.p.:
232.9–233.6 C; 1H NMR (300MHz, DMSO-d6) d 11.79 (br s, NH),
7.85 (d, J¼ 7.9 Hz, 1H), 7.15 (s, 1H), 6.95 (d, J¼ 8.2 Hz, 1H), 3.83(br
s, 4H), 3.62 (s, 2H), 2.86 (br s, 4H), 2.67 (s, 3H), 2.38 (s, 3H); IR (KBr):
3446, 3181, 2813, 1634, 1455, 1330, 821 max/cm
1; MS (ESI) m/z:
272 [MþH]þ.
2.1.4. General procedure for the synthesis of final compounds
8, 11–22
1-(2,6-Dimethyl-1H-indol-3-yl)-2-(piperazin-1-yl)ethan-1-one (7)
(1 eq) was dissolved in dichloromethane dry. To the resulting solu-
tion EDCI (1 eq), TEA (2 eq), DMAP (0.1 eq) and the appropriate
carboxylic acid (1 eq) were sequentially added. The reaction was
stirred under nitrogen at room temperature overnight.
Evaporation of the solvent gave a crude which was directly puri-
fied by column chromatography.
2.1.5. 2-(4-Benzoylpiperazin-1-yl)-1-(2,6-dimethyl-1H-indol-3-yl)e-
than-1-one (8)
Yellow solid; yield 29%; column eluants: EtOAc, EtOAc/MeOH 9:1;
m.p.: 213.8–214.3 C. 1H NMR (300MHz, DMSO-d6) d 11.72 (br s,
NH), 7.85 (d, J¼ 8.2 Hz, 1H), 7.46–7.40 (m, 5H), 7.15 (s, 1H), 6.96 (d,
J¼ 7.9 Hz, 1H), 3.67 (br s, 4H), 3.18 (br s, 2H) 2.67 (s, 3H), 2.61–2.56
(m, 4H), 2.38 (s, 3H); 13C NMR (75MHz, DMSO-d6) d 192.8, 169.5,
144.7, 136.5, 135.7, 131.5, 130.0, 129.0, 127.5, 125.1, 123.4, 121.2,
112.9, 111.6, 66.9, 53.2, 53.1, 21.7, 15.7; IR (KBr) 3189, 2990, 2828,
1609, 1446, 1282, 807 max/cm
1. MS (ESI) m/z: 374 [M–H]þ. Anal.
Calcd. for C23H25N3O2: C, 73.57; H, 6.71; N, 11.19; found C, 73.76;
H, 6.94; N, 10.85.
2.1.6. 2-(4-(4-Chlorobenzoyl)piperazin-1-yl)-1-(2,6-dimethyl-1H-
indol-3-yl)ethan-1-one (11)
Yellow solid; yield 33%; column eluants: EtOAc, EtOAc/MeOH 9:1;
m.p.: 240.7–241.3 C; 1H NMR (300MHz, DMSO-d6) d 11.70 (br s,
NH), 7.85 (d, J¼ 7.9 Hz, 1H), 7.50 (br d, AA’XX’, 2H), 7.42 (br d,
AA’XX’, 2H), 7.14 (s, 1H), 6.95 (d, J¼ 8.2 Hz, 1H), 3.67 (br s, 4H),
3.33 (br s), 2.67 (s, 3H), 2.61–2.56 (m, 4H), 2.38 (s, 3H); 13C NMR
(75MHz, DMSO-d6) d 193.17, 168.4, 144.8, 135.7, 135.2, 134.8,
131.5, 129.5, 129.1, 125.1, 123.5, 121.2, 112.7, 111.6, 53.14, 53.14,
52.9, 21.7, 15.7. IR (KBr): 3225, 2793, 2358, 1609, 1442, 1261, 864
max/cm
1. MS (ESI) m/z: 410 [MþH]þ. Anal. Calcd. for C23H24
ClN3O2: C, 67.39; H, 5.90; N, 10.25; found C, 67.11; H, 6.12;
N, 10.54.
2.1.7. 1-(2,6-Dimethyl-1H-indol-3-yl)-2-(4-(4-methoxybenzoyl)piper-
azin-1-yl)ethan-1-one (12)
Yellow solid; yield 53%; column eluants: EtOAc, EtOAc/MeOH 9:1;
m.p.: 219.9–220.8 C.; 1H NMR (300MHz, DMSO-d6) d 11.70 (br s,
NH), 7.85 (d, J¼ 8.2 Hz, 1H), 7.38 (br d, AA’XX’, 2H), 7.14 (s, 1H),
6.99–6.94 (m, 3H), 3.79 (br d, 3H), 3.67 (br s, 2H), 3.51 (br s, 4H)
2.67 (s, 3H), 2.58 (br s, 4H), 2.38 (s, 3H); 13C NMR (75MHz, DMSO-
d6) d 192.8, 169.5, 144.6, 136.5, 135.7, 131.5, 130.0, 129.0, 127.5,
125.1, 123.4, 121.2, 112.8, 111.6, 66.9, 55.8, 53.2, 53.1, 21.7, 15.7; IR
(KBr): 3235, 3003, 2807, 1613, 1463, 1253, 977 max/cm
1; MS (ESI)
m/z: 406 [MþH]þ. Anal. Calcd. for C24H27N3O3: C, 71.09; H, 6.71;
N, 10.36; found C, 71.10; H, 6.75; N, 10.32.
2.1.8. 4-(4-(2-(2,6-Dimethyl-1H-indol-3-yl)-2-oxoethyl)piperazine-1-
carbonyl)benzonitrile (13)
Yellow solid; yield 23%; column eluants: EtOAc, EtOAc/MeOH 9:1;
m.p.: 243.9–244.8 C. 1H NMR (300MHz, DMSO-d6) d 11.70 (br s,
NH), 7.92–7.84 (m, 3H), 7.58 (br d, AA’XX’, 2H), 7.15 (s, 1H), 6.96 (br
d, 1H), 3.68 (br s, 4H), 3.29 (br s, 2H), 2.67 (s, 3H), 2.51 (br s, 4H),
2.38 (s, 3H); 13C NMR (75MHz, DMSO-d6) d 192.5, 166.3, 143.2,
139.4, 134.1, 131.6, 129.9, 126.8, 123.5, 121.9, 119.6, 117.4, 111.2,
111.1, 110.1, 65.1, 51.7, 51.2, 20.1, 14.1; IR (KBr): 3410, 3254, 2816,
2790, 2233, 1609, 1454, 1291, 979 max/cm
1; MS (ESI) m/z:
401[MþH]þ. Anal. Calcd. for C24H24N4O2: C, 71.98; H, 6.04; N,
13.99; found C, 72.13; H, 6.23; N, 14.08.
2.1.9. 1-(2,6-Dimethyl-1H-indol-3-yl)-2-(4-(thiophene-2-carbonyl)pi-
perazin-1-yl)ethan-1-one (14)
Yellow solid; yield 29%; column eluants: EtOAc, EtOAc/MeOH 9:1;
m.p.: 200.3–201.2 C; 1H NMR (300MHz, DMSO-d6) d 11.74 (br s,
NH), 7.86 (d, J¼ 8.2 Hz, 1H), 7.76 (br d, 1H), 7.41–7.40 (m, 1H),
7.15–7.10 (m, 2H), 6.96 (d, J¼ 8.2 Hz, 1H), 3.75–3.67 (m, 4H), 3.37
(br s, 2H) 2.68 (s, 3H), 2.62 (s, 4H), 2.38 (s, 3H); 13C NMR (75MHz,
DMSO-d6) d 192.8, 167.8, 144.7, 137.8, 135.7, 131.5, 130.0, 129.6,
127.7, 125.1, 124.1, 123.4, 121.2, 112.8, 111.6, 66.7, 53.3, 21.7, 15.7;
IR (KBr): 3270, 2927, 2793, 1642, 1454, 1261, 809 max/cm
1; MS
(ESI) m/z: 382[MþH]þ; Anal. Calcd. for C21H23N3O2S: C, 66.12; H,
6.08; N, 11.01; found C, 66.23; H, 6.26; N, 10.93.
2.1.10. 1-(2,6-Dimethyl-1H-indol-3-yl)-2-(4-nicotinoylpiperazin-1-
yl)ethan-1-one (15)
Yellow solid; yield 39%; column eluants: EtOAc, EtOAc/MeOH 9:1;
m.p.: 216.2–216.8 C; 1H NMR (300MHz, DMSO-d6) d 11.70 (br s,
NH), 8.65–8.61 (m, 2H), 7.87–7.82 (m, 2H), 7.50–7.45 (m, 1H), 7.15
(s, 1H), 6.95 (br d, 1H), 3.68 (br s, 4H), 3.37 (br s, 2H), 2.67 (s, 3H),
2.56 (br s, 4H), 2.37 (s, 3H); 13C NMR (75MHz, DMSO-d6) d 192.6,
167.2, 151.0, 148.1, 144.7, 135.7, 135.4, 132.3, 131.5, 125.1, 124.1,
123.5, 121.2, 116.2, 111.6, 66.7, 53.4, 52.9, 21.7, 15.7; IR (KBr): 3414,
3213, 2828, 1621, 1454, 1267, 1301, 817 max/cm
1; MS (ESI) m/z:
377 [MþH]þ; Anal. Calcd. for C22H24N4O2: C, 70.19; H, 6.43; N,
14.88; found C, 70.21; H, 6.44; N, 14.73.
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2.1.11. 1-(2,6-Dimethyl-1H-indol-3-yl)-2-(4-(2-methylbenzoyl)pipera-
zin-1-yl)ethan-1-one (16)
Yellow solid; yield 41%; column eluants: EtOAc, EtOAc/MeOH 9:1;
m.p.: 200.5–201.6 C; 1H NMR (300MHz, DMSO-d6) d 11.70 (br s,
NH), 7.85 (d, J¼ 8.2 Hz, 1H), 7.31–7.27 (m, 3H), 7.26–7.24 (m, 2H),
7.15 (d, 1H), 3.69 (br s, 2H), 3.34 (br s, 2H), 3.15 (br s, 2H), 2.67 (s,
3H), 2.51 (br s, 4H), 2.44 (s, 3H), 2.38 (s, 3H); 13C NMR (75MHz,
DMSO-d6) d 192.6, 169.0, 144.7, 135.7, 134.2, 131.8, 131.5, 130.7,
129.2, 126.4, 126.2, 123.4, 121.2, 112.8, 66.8, 53.5, 53.0, 46.8, 41.4,
21.7, 19.2, 15.7; IR (KBr): 3431, 3221, 2919, 2797, 1615, 1454, 1257,
748 max/cm
1; MS (ESI) m/z: 390 [MþH]þ. Anal. Calcd. for
C24H27N3O2: C, 74.01; H, 6.99; N, 10.79; found C, 74.01; H, 7.01;
N, 10.63.
2.1.12. 1-(2,6-Dimethyl-1H-indol-3-yl)-2-(4-(3-methoxybenzoyl)pi-
perazin-1-yl)ethan-1-one (17)
Yellow solid; yield 32%; column eluants: EtOAc, EtOAc/MeOH 9:1;
m.p.: 209.8–210.4 C; 1H NMR (300MHz, DMSO-d6) d 11.71 (br s,
NH), 7.85 (d, J¼ 7.9 Hz, 1H), 7.34 (t, 1H), 7.15 (br s, 1H), 7.02–6.92
(m, 4H), 3.78 (s, 3H), 3.68 (br s, 3H), 3.35 (br s, 3H), 2.67 (br s, 7H),
2.38 (s, 3H); 13C NMR (75MHz, DMSO-d6) d 192.7, 169.1, 159.7,
144.7, 137.9, 135.7, 131.5, 130.2, 125.1, 123.4, 121.2, 119.4, 115.7,
112.7, 111.6, 66.8, 55.8, 53.3, 53.11, 47.4, 21.7, 15.7; IR (KBr): 3131,
3049, 2944, 1651, 1455, 1292, 1130, 968 max/cm
1; MS (ESI) m/z:
406 [MþH]þ. Anal. Calcd. for C24H27N3O3: C, 71.09; H, 6.71; N,
10.36; found C, 70.85; H, 6.45; N, 10.76.
2.1.13. 2-(4-(3,4-Difluorobenzoyl)piperazin-1-yl)-1-(2,6-dimethyl-1H-
indol-3-yl)ethan-1-one (18)
Yellow solid; yield 27%; column eluants: EtOAc, EtOAc/MeOH 9:1;
m.p.: 233.8–235.0 C; 1H NMR (300MHz, DMSO-d6) d 11.71 (br s,
NH), 7.85 (d, J¼ 7.9 Hz, 1H), 7.56–7.47 (m, 2H), 7.28 (br s, 1H), 7.15
(s, 1H), 6.96 (d, J¼ 7.9 Hz, 1H), 3.68 (br s, 2H), 3.33 (br s, 2H), 2.67
(s, 3H), 2.51 (br s, 6H), 2.38 (s, 3H); MS (ESI) m/z: 412 [MþH]þ; IR
(KBr): 3252, 2919, 2795, 1618, 1469, 1286, 1046, 980 max/cm
1;
MS (ESI) 412 [MþH]þ. Anal. Calcd. for C23H23F2N3O2: C, 67.14; H,
5.63; N, 10.21; found C, 67.43; H, 5.79; N, 10.59.
2.1.14. 2-(4-(3-Chlorobenzoyl)piperazin-1-yl)-1-(2,6-dimethyl-1H-
indol-3-yl)ethan-1-one (19)
Yellow solid; yield 32%; column eluants: EtOAc, EtOAc/MeOH 9:1;
m.p.: 222.3–223.5 C; 1H NMR (300MHz, CDCl3) d 9.42 (br s, NH),
7.71 (d, J¼ 7.9 Hz, 1H), 7.40–7.25 (m, 4H), 7.04 (d, J¼ 8.2 Hz, 2H),
3.85 (br s, 4H), 3.47 (br s, 2H), 2.80 (br s, 1H), 2.68 (br s, 6H), 2.40
(s, 3H); 13C NMR (75MHz CDCl3,) d 192.5, 169.0, 144.7, 137.5,
135.3, 134.7, 132.3, 130.0, 127.3, 125.2, 124.0, 123.7, 120.6, 112.8,
111.4, 67.0, 53.7, 53.7, 29.6, 21.5, 15.7; IR (KBr): 3264, 2916, 2795,
1646, 1454, 1256, 978, 809 max/cm
–1; MS (ESI) m/z: 410 [MþH]þ.
Anal. Calcd. for C23H24ClN3O2: C, 67.39; H, 5.90; N, 10.25; found C,
67.38; H, 5.90; N, 10.24.
2.1.15. 1-(2,6-Dimethyl-1H-indol-3-yl)-2-(4-(4-methylbenzoyl)pipera-
zin-1-yl)ethan-1-one (20)
Yellow solid; yield 48%; column eluants: EtOAc, EtOAc/MeOH 9:1;
m.p.: 230.9–231.2 C; 1H NMR (300MHz, DMSO-d6) d 11.71 (br s,
NH), 7.86–7.82 (m, 1H), 7.31–7.23 (m, 4H), 7.15 (s, 1H), 6.96 (d,
J¼ 7.9 Hz, 1H), 3.69 (br s, 2H), 3.35 (br s, 4H), 2.67 (s, 3H), 2.51. IR
(KBr): 3228, 2915, 2792, 1607, 1454, 1260, 979 max/cm
1; MS (ESI)
m/z: 390 [MþH]þ; Anal. Calcd. for C24H27N3O2: C, 74.01; H, 6.99;
N, 10.79; found C, 74.12; H, 7.02; N, 10.79.
2.1.16. 2-(4-(Cyclopentanecarbonyl)piperazin-1-yl)-1-(2,6-dimethyl-
1H-indol-3-yl)ethan-1-one (21)
Brown oil; yield 61%; column eluants: EtOAc, EtOAc/MeOH 9:1; 1H
NMR (300MHz, CDCl3) d 9.00 (br s, NH), 7.73 (d, J¼ 8.2 Hz, 1H),
7.26 (br d, 1H), 7.12 (s, 1H), 7.05 (d, J¼ 8.2 Hz, 1H), 3.83 (s, 2H),
3.75 (br s, 2H), 3.63 (br s, 2H), 2.80–2.71 (m, 7H), 2.45 (s, 3H),
1.92–1.46 (m, 7H); IR (KBr): 3253, 2944, 2862, 1650, 1620, 1455,
1234, 957 max/cm
1; MS (ESI) m/z: 368 [MþH]þ; Anal. Calcd. for
C22H29N3O2: C, 71.90; H, 7.95; N, 11.43; found C, 72.23; H, 8.31;
N, 11.32.
2.1.17. 1-(4-(2-(2,6-Dimethyl-1H-indol-3-yl)-2-oxoethyl)piperazin-1-
yl)heptan-1-one (22)
Brown oil; yield 76%; column eluants: EtOAc, EtOAc/MeOH 9:1; 1H
NMR (300MHz, CDCl3) d 10.25 (br s, NH), 7.68 (d, J¼ 8.2 Hz, 1H),
7.08 (s, 1H), 7.00 (d, J¼ 7.9 Hz, 1H), 3.83 (s, 2H), 3.73 (br s, 2H),
3.56 (br s, 2H), 2.77–2.71 (m, 3H), 2.62 (s, 3H), 2.38 (s, 3H),
2.32–2.27 (m, 5H), 1.59–1.54 (m, 2H), 1.26 (br s, 4H), 0.85 (br t, 3H);
13C NMR (75MHz, CDCl3) d 191.7, 172.4, 145.4, 135.5, 132.1, 124.0,
123.6, 120.4, 112.4, 111.6, 66.2, 53.3, 53.1, 45.3, 41.2, 34.5, 31.6,
28.9, 25.0, 22.5, 21.5, 15.6, 14.1; IR (KBr): 2927, 2857, 1731, 1645,
1455, 1434, 1234, 668 max/cm
1; MS (ESI) m/z: 384 [MþH]þ;
Anal. Calcd. for C23H33N3O2: C, 72.03; H, 8.67; N, 10.96; found C,
72.03; H, 8.73; N, 11.21.
2.2. Cell lines
Madin-Darby canine kidney (MDCK) cells stably expressing One
Strep Tag DGKa (OST-DGKa) were prepared by infecting MDCK
cells with a vector expressing an inducible OST tagged DGKa con-
structs17. MDCK cells infected with empty vector were used as
controls. MDCK cells were cultured in MEM (minimal essential
medium) with 5% FBS (foetal bovine serum) and 1% antibiotic–an-
timycotic solution. Routinely, cells were splitted every 3–4 days
with trypsin–EDTA 0.25% in standard 100mm dishes.
Human embryonic kidney 293T cells (10 cm2 plates) were cul-
tured in RPMI with 10% FBS and 1% penicillin/streptomycin and
cultures were maintained by splitting them for every 2–3 days
using trypsin–EDTA 0.25%.
Michigan Cancer Foundation 7 (MCF7) cells were cultured in
DMEM with 10% FBS þ 1% penicillin/streptomycin and cultures
were maintained by splitting them for every 2–3 days using
trypsin–EDTA 0.25%.
2.3. Primary cells
PBL were isolated from healthy anonymous human donors by
Ficoll-Paque PLUS (GE Healthcare, Chicago, IL) density gradient
centrifugation, washed, and resuspended at 2 106 cell/mL in
RPMI-GlutaMAX containing 10% heat inactivated FCS, 2mM glu-
tamine, and 100U/mL of penicillin and streptomycin. T cells were
activated with 1 mg/mL anti-CD3 (UCHT1) and anti-CD28 (clone
CD28.2) antibodies. After three days, activated T cells were
washed and cultured in medium additionated of 100 IU/mL rhIL-2
(Peprotech, Rocky Hill, NJ) at 1.2 106 cells/mL for 7 days by
changing media for every 2–3 days.
Human monocytes were isolated from healthy anonymous
human buffy coats (provided by the Transfusion Service of
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Ospedale Maggiore della Carita, Novara, Italy) by the standard
technique of dextran sedimentation and Histopaque (density ¼
1.077 g cm3, Sigma-Aldrich, Milano, Italy) gradient centrifugation
(400g, 30min, room temperature) and recovered by fine suction
at the interface, as described previously32. Purified monocytes
populations were obtained by adhesion (90min, 37 C, 5% CO2) in
serum-free RPMI 1640 medium (Sigma-Aldrich, Milano, Italy) sup-
plemented with 2mM glutamine and antibiotics. Cell viability (try-
pan blue dye exclusion) was usually >98%.
2.4. Preparation of DGKa enriched homogenates
Large cultures of MDCK cells for enzyme preparation were done
by plating 5 106 cells in 245mm2 dishes. Once they reached
nearly 70% confluence, cells were treated with doxycycline (1 mg/
mL, two days). After two days of treatment, each plate was
washed in cold PBS and cells homogenised in 5mL of homogen-
ate buffer (25mM Hepes (pH 8), 20% glycerol, 135mM NaCl, 5mM
ethylenediaminetetraacetic acid (EDTA), 1mM ethylene glycol-bis(-
beta-aminoethyl ether)-N,N,N0,N0-tetraacetic acid (EGTA), 1mM
sodium orthovanadate, and protease inhibitor cocktail) for each
dish. Cells were collected with a rubber scraper, homogenised by
passing them through a 29G-needle syringe 20 times and stored
in aliquots at –80 C. Presence of OST-DGKa was confirmed by
western blotting and enzyme assay, transduced DGKa has an
activity >100 folds the endogenous DGK.
2.5. Preparation of DGKf and DGKh enriched homogenates
293T cells were transiently transfected with indicated DGK isoform
plasmid DNA using Lipofectamine 3000, Invitrogen (Carlsbad, CA).
Forty eight hours after transfection, cells were harvested and
homogenised with a 29G-needle using 500 mL of homogenate
buffer for each dish and immediately stored in aliquots at –80 C.
Cells transfected with empty vector were used as controls, overex-
pressed DGK has an activity >50 folds the endogenous.
2.6. DGK assay
Essentionally, the same procedure was followed as reported previ-
ously in Velnati et al.9 In brief, DGK activity was assayed by meas-
uring initial velocities (5min at 27 C) in presence of saturating
substrate concentrations. Reaction conditions: 0.9 mg/mL 1,2-dio-
leoyl-sn-glycerol, 5mM ATP, 0.01 mCi/mL [c32P]-ATP, 1mM sodium
orthovanadate, 10mM MgCl2, 1.2mM EGTA in 7.5mM Hepes pH
812. Reaction mixture is assembled mixing enzyme (24.5 mL of
homogenate), 100 inhibitor or DMSO (0.5 mL), 5 ATP solution
(10 mL of 25mM ATP, 0.05 mCi/mL [c32P]-ATP (Perkin-Elmer, Milan,
Italy), 5mM sodium orthovanadate, 50mM MgCl2), and 3.3 DAG
solution (15 mL of 3 mg/mL 1,2-dioleoyl-sn-glycerol resuspended by
sonication in 4mM EGTA in 25mM Hepes pH 8). The reaction was
stopped after 5min by adding 200 mL of freshly prepared 1 M HCl
and lipid was extracted by adding 200 mL of CH3OH:CHCl3 1:1
solution and vortexing for 1min. The two phases were separated
by centrifugation (12,000 RCF for 2min). Twenty-five microlitres of
the lower organic phase was spotted in small drops on silica TLC
plates. TLC was run 10 cm and dried before radioactive signals
were detected by GS-250 molecular imager and was quantified by
quantity one (Bio-Rad, Hercules, CA) software assuring the absence
of saturated spots.
Percentage residual activity was calculated as follows: (OST-
DGKa homogenate with inhibitor – vector homogenate)/(OST-
DGKa homogenate with DMSO – vector homogenate)100.
2.7. Superoxide anion (O22) production
All the experiments were performed in triplicate using cells iso-
lated from each single donor.
Monocytes (250,000 cells/well) were treated for 1 h with the
indicated drugs (10mM) with or without serotonin (1 mM). Then,
cells were stimulated with phorbol 12-myristate 13-acetate (PMA;
Sigma-Aldrich, Milano, Italy) 1 mM for 30min. PMA is a well-known
stimulus that induces a strong and significant respiratory burst via
PKC activation33. Superoxide anion production was then evaluated
by the superoxide dismutase (SOD)-sensitive cytochrome C (CytC)
reduction assay and expressed as nmoles CytC reduced/106 cells/
30min, using an extinction coefficient of 21.1mM. To avoid inter-
ference with spectrophotometrical recordings, cells were incu-
bated with RPMI 1640 without phenol red, antibiotics, and FBS.
2.8. RICD assay in SAP silenced T cells
Activated human PBLs were transfected with 200pmol of siRNA oli-
gonucleotides specific for the target protein (Stealth Select siRNA;
Life Technologies, Carlsbad, CA) or a non-specific control oligo (Life
Technologies, Carlsbad, CA). Transient transfections were performed
using Amaxa nucleofector kits for human T cells (Lonza, Basel,
Switzerland) and the Amaxa Nucleofector II or 4D systems (pro-
grammes T-20 or EI-115). Cells were cultured in IL-2 (100 IU/mL) for
four days to allow target gene knockdown. Knockdown efficiency
was periodically evaluated by Western blotting.
Non-specific Stealth RNAi Negative Control Duplexes (12935-300,
Life Technologies, Carlsbad, CA) were used as a negative control.
siRNA SAP: sense strand UGUACUGCCUAUGUGUGCUGUAUCA,
antisense strand UGAUACAGCAGACAUAGGCAGUACA.
To test restimulation induced cell death, activated T cells (105
cells/well) were plated in triplicate in 96-well round-bottom plate and
treated with anti-CD3 (clone OKT3) (10ng/mL) in RPMI-GlutaMAX
supplemented with 100 IU/mL rhIL-2 for 24h. In these assays, inhibi-
tors (10mM) were added 30min before the restimulation with OKT3.
24h after treatment, cells were stained with 20ng/mL propidium iod-
ide and collected for a constant time of 30 s per sample on Attune
Nxt Flow Cytometer (Thermo Fisher Scientific, Waltham, MA). Cell
death is expressed as % cell loss and calculated as:
% cell loss ¼ 1 number of viable cells in sample
number of viable cells in control
 
 100
 
Results were expressed as mean± standard error of the mean
(SEM). We always compared controls and SAP silenced lympho-
cytes from the same donors as there is a large individual variabil-
ity in RICD sensitivity.
2.9. Migration assays
Cell migration assays were performed using the Culture-Insert 2
well in m-Dish (ibidi GmbH, Martinsried, Germany).
Briefly, 25,000 MCF7 cells were plated in each well and cultured
for 24h. The day after, the culture insert was removed and the cells
were washed with PBS before treating them with respective DGKa
inhibitors (10mM) or DMSO for 15 h in complete medium (DMEM
10% FBS þ 1% penicillin/streptomycin), while medium without FBS
was used as a negative control for migration.
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Phase-contrast pictures were taken immediately after treatment
(0 h) and after 15 h under 5 magnification.
Finally, wound areas were determined using ImageJ software
(NIH, , Bethesda, MD). Wound reduction was calculated by using
the following formula: (wound area at 15 h/wound at 0 h)100,
the values obtained were expressed as the percentage of wound
area compared to the initial area.
2.10. Quantification and statistical analysis
Data for the screen on OST-DGKa homogenates are the mean of
duplicates. The compounds showing inhibitory activity in this
assay were tested >4 times and the mean± SEM is reported.
To calculate IC50 values of active inhibitors, the inhibitor activ-
ity was measured at least three times at 0.1, 1.0, 10.0, and
100.0 mM concentration. Data were analysed using [inhibitor] vs.
normalised response parameters with least square [ordinary] curve
fitting method in GraphPad PRISM 8.0 software (GraphPad
Software, La Jolla, CA) mentioning 95% confidence interval and
IC50 values always greater than 0.0. Graph shows the mean± SEM
of inhibitor activity at the indicated concentration. In all the
experiments, the data were normalised with the controls.
Evaluation of in vitro assays across multiple treatments (RICD),
SOD-sensitive CytC reduction assay, migration assays were
analysed by using one-way ANOVA with multiple comparisons cor-
rection using GraphPad PRISM 8.0 software (GraphPad Software,
La Jolla, CA). Error bars are described in figure legends as ± SEM
or ± SD where appropriate. A single, double, triple and four aster-
isk denotes significance of a p value 0.05, 0.01, 0.001, and
0.0001 respectively in all experiments.
2.11. Pharmacophoric model
A representative 3D structure of each compound was generated
using OMEGA2 software34–36. The generated file was used to gen-
erate a pharmacophore model with the Pharmagist web server
(bioinfo3d.cs.tau.ac.il/PharmaGist/)37.
3. Results
3.1. Chemistry
At the beginning, we purchased 14 analogues of Amb639752 by
vendors (Figure 3), while one analogue (2), being not commer-
cially available, was synthesised (see Supplementary material). All
the compounds were evaluated for their inhibitory activity on
DGKa at a concentration of 100mM (Table 1).
Figure 3. First set of compounds tested for their inhibitory activity on DGKa.
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Each inhibitor was tested in duplicate at least once, and DGKa
activity was expressed as percentage of residual DGKa activity
compared to DMSO control in the same assay. Assay uses OST-
DGKa overexpressing cell lysates in presence of saturating exogen-
ous DAG and ATP. We considered R59022 (commercially available)
and the lead compound Amb63975230 as our reference mole-
cules. As expected, our reference inhibitors R59022 and
Amb639752 featured 73% and 96% inhibition respectively, con-
firming the quality of data obtained.
This first screening showed us how Amb639752 exhibits a rigid
structure activity relationship. Indeed, both the methyl groups on
the 2,6 position of indole are mandatory, the NH indole cannot be
alkylated as well as ramifications on the alkyl chain are detrimen-
tal. We then focussed our attention on furan ring knowing its
intrinsic toxicity via metabolic activation38. Unfortunately, there
were no analogues available by vendors. Our first goal was to
replace the furan moiety with the phenyl ring, investigating two
different synthetic pathways.
In the first one, the commercially available 2,6-dimethyl-1H-
indole 3 was acylated with 2-chloroacetyl chloride 4, in the pres-
ence of DBU in dichloroethane39 to give the derivative 5 90%
yield. Then, the acylated compound 5 was reacted with N-Boc
piperazine in the presence of potassium carbonate and potassium
iodide to afford the piperazinic derivative 6 in 63% yield. Boc
deprotection with trifluoroacetic acid, followed by coupling with
benzoic acid using the condensing agent EDCI afforded the final
compound 8 (Scheme 1).
In the second synthetic strategy, we initially coupled the ben-
zoic acid with N-Boc piperazine in the presence of EDCI to give
piperazinic derivative 9 in 49% yield. Boc deprotection gave in
quantitative yield the compound 10. Due to its high aqueous
solubility, solvent was evaporated and the crude as trifluoroace-
tate salt was directly used for the next step, where it was reacted
with the acylated indole 5 to give the final compound 8 in 25%
yield (Scheme 2) (see Supplementary material for full syn-
thetic details).
Overall yield calculation was 11% for both strategies, but with
the first route it was possible to use a common synthetic inter-
mediate 7 which can be coupled with different carboxylic acids.
Furthermore, the second route requires more purification steps.
For this reason, we applied the first route and coupled the
advanced intermediate 7 with 12 different carboxylic acids (Figure
4) to afford compounds 11–22 (Figure 5).
All those molecules were dissolved in DMSO and tested at a
concentration of 100mM for the ability to inhibit DGKa using
equal amounts of DMSO as control. We identified eight com-
pounds capable of reducing OST-DGKa activity similar or superior
to R59022 (Table 2).
3.2. Potency and isoform specificity of active molecules
To measure the inhibitor potency, we determined the IC50 values
for the compounds that resulted active when tested at 100 mM by
measuring the residual OST-DGKa activity over a dose range of
inhibitor concentrations (0.1mM, 1.0mM, 10.0 mM, and 100.0 mM).
Table 1. Inhibitory activity on DGKa (I).
Compound Residue activity at 100 mM
R59022 27
R59949 28
Amb639752 4
Amb758897 67
Amb37496 114
Amb626577 127
Amb1926062 88
Amb94966 196
Amb730692 45
Amb98433 81
Amb18718 135
Amb726054 126
Amb731111 130
Amb22018852 160
Amb687392 115
Amb758592 150
Amb629700 101
2 135
Scheme 1. The first synthetic route for the compound 8.
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For R59022 and Amb639752, we measured IC50 values of
15.2 ± 5.8mM and 6.9 ± 3.0mM respectively which were comparable
to previous reports using similar assay conditions9. Considering
those two as reference/template compounds, we measured the
IC50 values of 8, 11, 12, 13, 14, 16, 19, and 20 as 3.2 ± 1.0,
1.6 ± 0.4, 3.6 ± 1.2, 6.9 ± 2.3, 3.0 ± 1.0, 32.8 ± 11.5, 49.7 ± 31.7, and
1.8 ± 0.4mM, respectively, signifying that their activity is equal or
superior to the template compounds (Figure 6).
Due to their higher IC50 values, we thus decided to exclude 16
and 19 for further experiments. In summary, we recognised six
compounds with equal or superior inhibitory activity compared to
commercially available DGKa inhibitors.
To check the isoform specificity of those active molecules, we
tested them, along with Amb639752, for their ability to inhibit
DGKa, DGKf (the other major DGK isoform expressed in lympho-
cytes), and the more distantly related and widely expressed DGKh.
At the highest concentration of 100 mM, all those molecules
resulted in highly specific against DGKa as like their parent mol-
ecule, Amb639752 by completely inhibit DGKa whereas they do
not have significant effects on DGKf and DGKh apart from 20
which, at the contrary, acts as an activator of DGKh (Figure 7).
3.3. Activity of compounds on serotonin receptors
R59022, R59949, and ritanserin feature a dual activity as DGKa
inhibitors and serotonin receptor antagonists25. Conversely,
Amb639752 was reported as a selective DGKa inhibitor which has
no effects on serotonin activity9. Thus, we investigated whether
the active molecules identified affect serotonin signalling.
To this purpose, we measured the effect of serotonin on
PMA-induced oxidative burst in human monocytes. As previously
shown, 1 mM serotonin reverses the oxidative burst to control
values33. Known serotonin receptor antagonists ritanserin and
ketanserin (10 mM) impaired serotonin action, while pure DGKa
inhibitors such as Amb639752 had no effect (Figure 8). These
data indicate that this assay is sensitive to perturbations in sero-
tonin signalling independently of activity against DGKa.
Interestingly, as like Amb639752, all the newly synthesised
active molecules did not affect serotonin action (Figure 8), indi-
cating that all those molecules are not serotonin receptor
antagonists.
3.4. DGKa inhibitors restore RICD in SAP deficient T cells
Ruffo et al. demonstrated that the defective RICD observed in T
cells from XLP-1 patients was rescued by silencing DGKa expres-
sion or by pre-treatment with DGKa inhibitors R59949 or R590228.
Interestingly, R59022 also showed beneficial effects in an in vivo
model of XLP-1, but due to its poor pharmacological proprieties,
its use in human patients results unlikely. We therefore tested the
effect all those active molecules along with Amb639752 on RICD
sensitivity of SAP-deficient T cells. As additional controls, we also
included ritanserin and ketanserin to evaluate the contribution of
serotonin antagonism to the effects observed.
To evaluate inhibitor efficacy in physiological context, we mod-
elled XLP-1 by silencing SAP in primary peripheral blood T lym-
phocytes (PBLs) and restimulating them with anti-CD3 antibody
(OKT3 10 ng/mL, 24 h). We pre-treated the cells with the indicated
Scheme 2. The second synthetic route for the compound 8.
Figure 4. Carboxylic acids used.
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inhibitors for 30min at a concentration of 10mM8. In control
siRNA-transfected cells, DGKa inhibitors poorly affect RICD, with
Amb639752, 11 and 14 slightly reducing it (Figure 9). Conversely,
DGKa inhibitors significantly rescued the apoptotic defect of SAP-
deficient T cells although not reaching control levels. At 10mM, all
the new molecules showed an efficacy comparable to Amb637952
and ritanserin used as positive reference molecules. Conversely,
the serotonin antagonist ketanserin is inactive, excluding the
involvement of serotonin receptors in rescuing the RICD in SAP-
deficient T cells (Figure 9).
In summary, these data confirm that the newly identified DGKa
inhibitors can rescue RICD susceptibility in T cell models of XLP-1
suggesting a putative use for XLP-1 therapy.
Figure 5. Putative DGKa inhibitors synthesised. In brackets the yield of the coupling reaction with the common intermediate 7.
Table 2. Inhibitory activity on DGKa (II).
Compound Residue activity at 100 mM IC50 (mM)
8 5 3.2
11 6 1.6
12 6 3.6
13 14 6.9
14 6 3.0
15 89 –
16 27 32.8
17 41 –
18 47 –
19 26 49.7
20 3 1.8
21 39 –
22 48 –
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3.5. DGKa inhibitors reduce migration of the cancer cells (MCF7)
Previous studies conducted in our laboratory demonstrated that
the inhibition of DGK activity decreases chemotaxis, proliferation,
migration, and invasion of many cancer cell lines12–14. To evaluate
if our newly synthetised DGKa inhibitors were effective in
impairing cancer cell migration, we measured serum induced
wound healing in MCF7 breast cancer cells in presence of 10 mM
inhibitor. In presence of serum, none of the inhibitors is toxic for
MCF7 cells even after prolonged treatment (data not shown).
After 15 h of treatment, all the newly synthesised active molecules
Figure 6. Dose–response curves for novel DGKa inhibitors. Dose–response of the most active compounds along with their IC50 values. Data from at least three inde-
pendent experiments performed in triplicate.
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equally reduced cell migration when compared to the vehicle
(DMSO) delaying wound closure (Figure 10).
Besides being in good agreement with the notion that DGKa is
required for cancer cells migration, this observation indicates that
our new DGKa inhibitors reduce cancer cell motility, suggesting a
potential utility in a metastasis setting.
3.6. Generation of a pharmacophore hypothesis
From the data obtained, it is possible to identify some key phar-
macophoric points crucial for the biological activity of the Amb
compounds on DGKs namely: (i) a basic nitrogen; (ii) the methyl
groups at the 2 and 6 position of the indole nucleus, and (iii) a
(hetero)aromatic ring. This information allows us to build a four-
point pharmacophoric model represented in Figure 11 superim-
posed with the minimised structure of compound 11. Although,
we are not able to evaluate the importance of the two carbonyl
groups, it represents the first attempts in order to identify the
minimum structural request to interact with DGK catalytic site
considering the molecular structure of the four most active inhibi-
tors discovered to date (Amb639752, ritanserin, R59022, and
R59949). We feel that this model might be useful to identify novel
Figure 7. Isoform specificity of novel DGKa inhibitors. 293T cells were transfected with different DGK isoforms (A – DGKa, B – DGKf, C – DGKh, respectively) or empty
vectors and homogenised. All the molecules were tested at 100lM for their capacity to inhibit the DGK activity of the different isoform homogenates. Data are
means± SEM of at least three independent experiments performed in triplicate.
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Figure 8. Novel DGKa inhibitors do not affect serotonin signalling. Human mono-
cytes were pre-incubated for 1 h with the indicated drugs in absence or presence
of serotonin and then stimulated with PMA 1 mM for 30min ( control unstimu-
lated cells, PMA stimulated cells,  PMA and serotonin stimulated cells).
Results are expressed as n moles of reduced cytochrome C/106 cells. Data are
means± SEM of 10 independent experiments performed in triplicate.
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Figure 9. DGKa inhibitors partially restores apoptosis in SAP deficient lympho-
cytes. Lymphocytes from normal subjects were transfected with control or SAP
specific siRNA ( control siRNA,  SAP siRNA). After 4 days, the cells were
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Figure 10. Novel DGKa inhibitors slow tumour cell migration. MCF7 monolayer
was wounded and treated for 15 h with serum in presence of our new DGKa
inhibitors (10lM) or vehicle (DMSO). Results are expressed as the percentage of
wound area compared to the initial area. Data are the mean± SEM of nine inde-
pendent experiments.
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compounds active on DGKa through more targeted virtual screen-
ing campaigns, overcoming the current scaffolds.
4. Discussion
As a key component of several signal transduction pathways,
DGKa represent an emerging pharmacological target. We have
demonstrated the efficacy of DGKa inhibitors for XLP-1 treatment8,
while others have proposed them for cancer treatment22 and to
remove immune-checkpoints promoting immune vigilance against
cancer40. Commercially available DGKa inhibitors are limited by
poor specificity25,41 and pharmacokinetic20. The CU-3 molecule
described by other features a noteworthy activity and specificity
but its reactive chemical structure make unlikely an in vivo use30.
With intent of developing molecules suitable for therapeutic use
we selected Amb639752 as a novel inhibitor with remarkable
DGKa activity. Amb639752 also features improved selectivity for
DGKa as it does not affect serotonin signalling9. Despite numerous
efforts a structure of mammalian DGKs is still missing, thus we
decided to explore the structure–activity relationship of this mol-
ecule to improve its activity and pave the way for further develop-
ments. Our efforts allowed us to build a pharmacophoric model
for DGKa inhibitors characterised by three required features. We
also characterised a set of novel compounds with improved IC50
in the low mM range and identified the most profitable synthetic
route for them. The mode of DGKa inhibition by those molecules
is still unknown apart for ritanserin, which binds at the same time
the DGKa catalytic accessory domain and the C1 domain puta-
tively promoting a close inactive conformation41.
The second-generation inhibitors we described in this work
maintain the specificity of Amb639752 as they not affect DGKf,
the predominant isoform of lymphocytes42 and the broadly
expressed DGKh43. Those DGKa inhibitors are active in a lympho-
cyte based XLP-1 assay and in a cancer cell migration assay, hold-
ing the promise for a potential therapeutic application. However,
their efficacy is still to be determined in in vivo models of disease
where some of the parental compounds showed efficacy but poor
pharmacokinetic8,20.
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